Related Experiment Video

Updated: Apr 4, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K

A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study

Hisao Ogawa1, Hirofumi Soejima2, Kunihiko Matsui3

  • 1Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan ogawah@kumamoto-u.ac.jp.

European Journal of Preventive Cardiology
|September 2, 2015
PubMed

Insights

Angiotensin II receptor blocker (ARB) therapy significantly improved urinary albumin creatinine ratio (UACR) and plasma brain natriuretic peptide (BNP) levels in hypertensive patients compared to standard therapy, offering novel cardiovascular and renal risk insights.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Hypertension management aims to reduce cardiovascular and renal events.
  • Biomarkers like UACR and BNP are crucial for risk stratification.
  • Comparing ARB therapy with standard non-ARB therapy provides insights into treatment efficacy.

Purpose of the Study:

  • To compare the effects of ARB therapy versus non-ARB standard therapy on UACR and plasma BNP levels.
  • To evaluate the incidence of cardiovascular composite events in hypertensive patients under different treatments.
  • To investigate the relationship between biomarker changes and cardiovascular events.

Main Methods:

  • Multicenter, open-label, randomized, parallel-group comparative study.
  • Investigated UACR and plasma BNP changes over three years.
  • Assessed cardiovascular composite events and biomarker associations.

Main Results:

  • ARB group showed significant improvements in UACR and plasma BNP compared to the non-ARB group.
  • Fewer cardiovascular events occurred in the ARB group, though not statistically significant.
  • Baseline UACR and plasma BNP levels predicted cardiovascular events.

Conclusions:

  • ARB treatment favorably impacts UACR and plasma BNP more than non-ARB treatment, independent of blood pressure.
  • BNP and UACR serve as significant predictors of cardiovascular and renal risk during antihypertensive treatment.
  • Provides novel insights into the role of ARBs in managing hypertensive patients.
Abstract

Keywords:
Angiotensin II receptor blockerbiomarkerbrain natriuretic peptidecardiovascular eventhypertensionurinary albumin creatinine ratio

More Related Videos

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.2K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
858
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
770
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
723